Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Partnership
Nordic Pharma Launches Authorized Generic of Maxitrol in the U.S.
Details : The partnership aims to launch an Maxitrol-Generic (Neomycin/Polymyxin B Sulfates/Dexamethasone) ophthalmic suspension, which treats and relieves bacterial eye infections.
Product Name : Maxitrol-Generic
Product Type : Steroid
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cross-linked Hyaluronic Acid
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nordic Pharma to Present Data on LACRIFILL® Gel for Dry Eye at Refractive Surgery Meeting
Details : LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
Product Name : Lacrifill
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : Cross-linked Hyaluronic Acid
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tegafur,Gimeracil,Oteracil
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive EMA Opinion for the Use of Teysuno in Metastatic Colorectal Cancer
Details : Based on the positive opinion from EMA, Teysuno (Tegafur) an oral fluoropyrimidine will be indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.
Product Name : Teysuno
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : Tegafur,Gimeracil,Oteracil
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Methotrexate is considered a cornerstone therapy for patients with rheumatoid arthritis (RA), with well-established safety and efficacy profiles and support in international guidelines.
Product Name : Nordimet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gliclazide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2016
Lead Product(s) : Gliclazide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2016
Lead Product(s) : Fish Oil
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparator Trial on the Relative Efficacy of Two Triglyceride Forms of Fish Oil
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 11, 2015
Lead Product(s) : Fish Oil
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2015
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2014
Lead Product(s) : Metformin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pro-Omega LDL
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 21, 2014
Lead Product(s) : Pro-Omega LDL
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
